Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 6/20 | 0.50 |
| ▸ | AXL | P30530 | 7/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28903782 | 0.79 | PIM1 (0.50) | PIM1AXLAURKATTKAURKB | |
| SCHEMBL9931699 | 0.76 | PRMT5 (0.47) | PIM1PRMT5WDR77 | |
| SCHEMBL28903837 | 0.75 | AXL (0.43) | PIM1AXLAURKATTKAURKB | |
| SCHEMBL28903730 | 0.72 | MAP4K1 (0.42) | PIM1AXLAURKATTKAURKB | |
| SCHEMBL13974671 | 0.71 | AURKA (0.44) | PIM1AXLAURKATTKAURKB | |
| SCHEMBL2348250 | 0.71 | LMNA (0.53) | PIM1PRMT5WDR77KDM5B | |
| SCHEMBL26146259 | 0.70 | SMARCA2 (0.44) | PIM1AXLAURKATTKAURKB | |
| Hydrochloric Acid SCHEMBL30368287 | 0.70 | LMNA (0.51) | PIM1PRMT5WDR77KDM5B | |
| SCHEMBL14851064 | 0.69 | LRRK2 (0.46) | PIM1AURKATTKAURKBINCENP | |
| SCHEMBL1493393 | 0.69 | ALDH1A1 (0.34) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688778-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Biogen MA Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024211696-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20170002011-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | NORGINE B.V. (NL) | 2017-01-05 | — | — | US | disclosed |
| US-20170002011-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | NORGINE B.V. (NL) | 2017-01-05 | — | — | US | disclosed |
| WO-2015097122-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | NORGINE B.V. (NL) | 2015-07-02 | — | — | WO | disclosed |
| EP-2470539-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025951-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | PIM1 290/4885AXL 364/4885AURKA 867/4885 |
| US-20170002011-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | CCR9, CCR1, CCR4 | PIM1 2954/4885AXL 1122/4885AURKA 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.